Daewoong, Neomics to develop anticancer drug

Published: 2009-07-07 06:56:00

Updated: 2009-07-07 06:56:00

Daewoong Pharm has recently signed a memorandum of understanding with Neomics Co., a local biopharmaceutical company, to develop, manufacture and commercialize a novel antitumor drug using AIMP2-DX2, a tumor gene that is involved in both cancer generating and suppressing mechanism

Both compani...

Fees

- Email service daily and homepage access.

$300 per month. ($3,240 per year)
5 Email holders per each company.
Anual contract base.

Latest News

Which are outstanding tetravalent vaccines even for the young?

Disease treated the most with clinical trial drugs is respiratory disorder like lung cancer

Who will be the next Pharmaceutical Safety Bureau Director?

Celltrion completes clinical trials for Remsima SC for European approval

Sales listed pharmas made in the first half of the year

TOP

BACK